Safety and Efficacy of SCH530348 in Addition to Standard of Care in Subjects With Acute Coronary Syndrome: Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER)
Description of Research
The purpose of this research study is to evaluate the clinical benefit of an investigational drug, SCH 530348, and how it may reduce the complications related to coronary events when given to patients with a history of chest pain.
Subject must be 18 years of age or older, and may be of either sex and of any race.
Subject must have a current clinical manifestation of NSTEACS
Additional screening criteria